UBS Group’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,659
| Closed | -$4.94K | – | 10577 |
|
|
2023
Q3 | $4.94K | Buy |
1,659
+859
| +107% | +$2K | ﹤0.01% | 7408 |
|
|
2023
Q2 | $1.94K | Sell |
800
-5,323
| -87% | -$8.76K | ﹤0.01% | 7833 |
|
|
2023
Q1 | $10.4K | Buy |
6,123
+3,060
| +100% | +$6.93K | ﹤0.01% | 7583 |
|
|
2022
Q4 | $5.36K | Buy |
3,063
+2,168
| +242% | +$5.27K | ﹤0.01% | 9188 |
|
|
2022
Q3 | $5K | Sell |
895
-92
| -9% | -$772 | ﹤0.01% | 9301 |
|
|
2022
Q2 | $16K | Buy |
987
+829
| +525% | +$12.1K | ﹤0.01% | 7255 |
|
|
2022
Q1 | $3K | Sell |
158
-1,731
| -92% | -$28.8K | ﹤0.01% | 9579 |
|
|
2021
Q4 | $36K | Buy |
+1,889
| New | +$53.5K | ﹤0.01% | 7216 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 10496 |
|
|
2021
Q2 | – | Sell |
-168
| Closed | -$11.8K | – | 10138 |
|
|
2021
Q1 | $17K | Sell |
168
-92
| -35% | -$7.92K | ﹤0.01% | 7543 |
|
|
2020
Q4 | $10K | Buy |
260
+188
| +261% | +$9.38K | ﹤0.01% | 7522 |
|
|
2020
Q3 | $4K | Sell |
72
-22
| -23% | -$1.77K | ﹤0.01% | 7473 |
|
|
2020
Q2 | $10K | Buy |
94
+36
| +62% | +$6.29K | ﹤0.01% | 7047 |
|
|
2020
Q1 | $11K | Buy |
58
+39
| +205% | +$9.95K | ﹤0.01% | 6895 |
|
|
2019
Q4 | $5K | Buy |
19
+14
| +280% | +$2.73K | ﹤0.01% | 7613 |
|
|
2019
Q3 | $1K | Sell |
5
-33
| -87% | -$7.91K | ﹤0.01% | 7883 |
|
|
2019
Q2 | $14K | Buy |
38
+35
| +1,167% | +$27.3K | ﹤0.01% | 6868 |
|
|
2019
Q1 | $3K | Buy |
+3
| New | +$4.86K | ﹤0.01% | 7372 |
|
|
2018
Q4 | – | Hold |
0
| – | -$1K | – | 8431 |
|
|
2018
Q3 | – | Sell |
-1
| Closed | -$2.89K | – | 7879 |
|
|
2018
Q2 | $2K | Sell |
1
-4
| -80% | -$13.5K | ﹤0.01% | 7759 |
|
|
2018
Q1 | $16K | Buy |
5
+3
| +150% | +$8.89K | ﹤0.01% | 6585 |
|
|
2017
Q4 | $4K | Buy |
2
+1
| +100% | +$2.73K | ﹤0.01% | 7485 |
|
|
2017
Q3 | $3K | Buy |
+1
| New | +$5.14K | ﹤0.01% | 7420 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 7419 |
|
|
2017
Q1 | – | Hold |
0
| – | -$3K | – | 8111 |
|
|
2016
Q4 | – | Sell |
-1
| Closed | -$5.11K | – | 7447 |
|
|
2016
Q3 | $4K | Hold |
1
| – | – | ﹤0.01% | 7225 |
|
|
2016
Q2 | $7K | Buy |
+1
| New | +$11.2K | ﹤0.01% | 6997 |
|
|
2016
Q1 | – | Hold |
0
| – | -$2K | – | 8363 |
|
|
2015
Q4 | – | Sell |
-1
| Closed | -$18.9K | – | 8048 |
|
|
2015
Q3 | $20K | Buy |
+1
| New | +$27.7K | ﹤0.01% | 6706 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8100 |
|
UBS Group's TMBR Position: Q4 2023 in Review
UBS Group sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2023, closing a stake of 1,659 shares — an estimated $4.94K sold.
UBS Group first reported a position in TMBR in Q3 2015 and held it in 24 quarters. The position peaked at $36K in Q4 2021. 0 funds tracked by Wall St. Rank hold TMBR as of Q4 2023.
- UBS Group reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- UBS Group sold 1,659 Timber Pharmaceuticals, Inc. shares in Q4 2023, an estimated $4.94K.
- UBS Group first reported a position in Timber Pharmaceuticals, Inc. in Q3 2015 and held it in 24 quarters.
- UBS Group's Timber Pharmaceuticals, Inc. position peaked at $36K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2023.
Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.